The origins of Biogen are in Geneva, Switzerland, where the company was founded in 1978. Biogen is the world’s third largest biotechnology company with 7,000 employees in 30 countries. From its foundation through to its recent return to Switzerland with a CHF 1.5bn investment in a new plant, the company’s successes bear to show many Swiss traits. The next-generation biologic manufacturing facility in Luterbach will create up to 600 new jobs.

**SWISS MARKERS AT BIOGEN**

- **Founded in Geneva 1978**
- **Established international headquarters in Zug in 2004**
- **Planned opening of major production site in Luterbach in 2019**

**INDICATIONS**

Therapies for serious medical conditions with few or no treatment options: multiple sclerosis, spinal muscular atrophy, biosimilars of advanced biologics.

**IN-LICENSING AGREEMENTS & PIPELINE**

Targeting devastating neurological diseases such as Multiple Sclerosis (MS), Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and Progressive Supranuclear Palsy (PSP). Various compounds licensed from, and developed in collaboration with, Neurimmune of Schlieren.

**SUCCESS CATEGORIES**

- ★ Completed achievement with lasting impact
- ★ Scientific breakthrough
- ★ New technology
- ★ Strong impact on society
- ★ Product approval and sustainable revenues
- ★ Involvement of one or more Swiss citizens
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland

**KNOWLEDGE**

Innovative scientific research with the goal of defeating devastating neurological diseases.